This author has not written his bio yet.
But we are proud to say that Melanie Piontek contributed 42 entries already.
EU Research Project Nano3Bio sums up: Promising achievements for winning future raw materials Since fossil raw materials are rapidly running out, their substitution by renewable resources is becoming increasingly important. In this process, the biological production of raw materials will have to play a leading role. The international project Nano3Bio, including ARTES Biotechnology has contributed […]
ARTES is pleased to announce a new EU based grant of patent for their well-proven virus-like-particle (VLP) technology platform METAVAX®. “The new patent integrates exactly in our existing patent portfolio and will further strengthen our technology offer”, said Dr. Melanie Piontek, Business Development Director of ARTES. “In combination with our proprietary yeast expression technology our […]
A consortium of 5 companies and the Fraunhofer-Institut für Lasertechnik ILT, aim to develop under the name of WAVESCATTER („Winkelauflösende Wellenleiter-Streulichtsonde für die Inline-Prozessanalytik“) a new kind of scattered light sensor for precise inline particle analytic. The project will be funded for a three year period by the German Federal Ministry of Education and Research […]
Meet us at the BIO International Convention taking place in San Diego, CA, USA June 19 -22. Michael Piontek, Managing Director at ARTES, will be present in the One-on-One Partnering. Contact us previously for organizing a personal meeting or drop us a notice via the partnering system. We look forward to meeting you! www.convention.bio.org/2017
Toady, ARTES has 15 year anniversary. In 2002 at May 10th Michael Piontek founded ARTES as R&D company, specialized in developing yeast cell lines for recombinant protein production. In 15 years ARTES has positioned itself as valued partner for the pharmaceutical and life science industry and it is now specialized in developing whole biotechnology production processes.
ARTES will head for London’s elite Mayfair district in February to take part in the ‘Dragons Den’ of veterinary medicine, the European Animal Health Investment Forum. This will be ARTES’ first participation in the high prestige investment networking event. ARTES will be represented by its Managing Director, Dr. Michael Piontek, who will be talking in particular […]
Langenfeld, Germany / Tehran, Iran ARTES Biotechnology and BioSun Pharmed announced to join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine in Iran. The agreed long-term collaboration involved the strength of both partners. ARTES Biotechnology GmbH (ARTES) is specialized in cell line and process development of virus like particle (VLP) […]
NEW DELHI, India I October 19, 2016 International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma today announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans. ICGEB has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine, […]
ARTES Biotechnology and Burnet Institute announce they have joined forces to develop a novel, effective vaccine to prevent transmission of hepatitis C virus (HCV). An HCV vaccine is urgently needed to prevent re-infection in people treated through antiviral therapies and reverse the high global mortality rates from infection-related liver cirrhosis or liver cancer, estimated by […]
ARTES Biotechnology, specialized in microbial cell line and process development for recombinant protein production and technology provider for high-quality biotechnological processes, join forces with the well-established contract manufacturing company Biosphere. Aim of this preferred cooperation is to offer a full range of services, starting from cell line generation up to industrial scale manufacturing in one […]
